Morbidity and mortality among low birth weight infants exposed to an intravenous vitamin E product, E-Ferol

Area of Science:

• Neonatal Medicine
• Clinical Toxicology
• Public Health

Background:

• An unusual clinical syndrome was reported in low birth weight infants exposed to an intravenous vitamin E preparation, E-Ferol.
• The E-Ferol product was marketed without prior safety testing and was voluntarily withdrawn.
• Ascites, liver and renal failure, and thrombocytopenia were key features of the reported syndrome.

Purpose of the Study:

• To investigate the association between E-Ferol exposure and adverse clinical outcomes in neonatal intensive care units.
• To determine the impact of E-Ferol on infant morbidity and mortality.
• To confirm the clinical syndrome linked to the vitamin E preparation.

Main Methods:

• A retrospective cohort study was conducted across seven neonatal intensive care units.
• Data were collected for infants admitted between November 1, 1983, and April 30, 1984.
• Inclusion criteria: infants weighing 2,000 g or less and surviving at least two days; 379 infants were studied, with 148 exposed to E-Ferol.

Main Results:

• Infants exposed to E-Ferol showed a higher likelihood of death compared to unexposed infants.
• E-Ferol-exposed infants were more prone to ascites, hepatomegaly, and thrombocytopenia.
• A significant association was found between E-Ferol use and increased infant morbidity and mortality.

Conclusions:

• The use of E-Ferol in neonatal intensive care units was associated with increased adverse health events and mortality.
• The study confirms the link between the intravenous vitamin E preparation and a severe clinical syndrome in neonates.
• This highlights the critical importance of pre-market safety testing for pharmaceutical products, especially for vulnerable populations.